Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

Information (Unaudited)(Dollars in millions, except per share data)Nine Months Ended

September 30, 2013Nine Months Ended

September 30, 2012GAAP
Reported

Adjustments

Non-GAAP
Adjusted(a)GAAP
Reported

Adjustments

Non-GAAP
Adjusted(a)Total Revenue

$17,304.3-

$

17,304.3

$16,646.0$

-

$

16,646.0Cost of sales3,521.6-3,521.63,548.2-3,548.2Operating Expenses(b)9,227.9-9,227.99,351.0-9,351.0Asset impairments,
restructuring and other
special charges(c)85.2(85.2)-77.1(77.1)-Other income (expense)(d)509.8(495.4)14.4726.0(787.8)(61.8)Income taxes 1,022.1(158.6)863.51,134.4(288.2)846.2Net income 3,957.3(251.6)3,705.73,261.3(422.5)2,838.8Earnings per share – diluted3.64(0.23)3.412.92(.38)2.54 

(a)We use non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles ("GAAP").  The items that we exclude when we provide non-GAAP measures or expectations are typically highly variable, difficult to predict, and of a size that could have a substantial impact on our reported operations for a period. We believe that these non-GAAP measures provide useful information to investors.  Among other things, they may help investors evaluate our ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets.  Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordan
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
2. Lilly Declares Fourth-Quarter 2013 Dividend
3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
11. Lilly Reports Second-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... paint a relatively optimistic picture of women,s chances of ... to the chest wall or skin, but not beyond. ... of size and whether they have involved lymph nodes, ... "locally advanced" tumors, suggesting that they are a relatively ... advanced breast cancers of this and other types account ...
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... Dec. 29 (HealthDay News) --,Concentrating on music can provide ... significant anxiety, according to a new study. Researchers ... the effectiveness of music as a pain reliever on ... a melody so they could identify the tones that ...
... HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay News) -- ... crushing depression and crippling anxiety to powerful delusions and hallucinations ... the imagined. And if that weren,t enough, they also ... world perceives their inner struggle. Stigma associated with ...
... 29 (HealthDay News) -- In some cases, memory loss among ... research suggests. Such strokes, which may not cause any ... and are found in roughly 25 percent of older adults, ... study of memory loss in the elderly is that it ...
... HealthDay Reporter , WEDNESDAY, Dec. 28 (HealthDay News) -- ... lengthen progression-free survival by about four months for women with ... Avastin (bevacizumab) will make a difference in overall survival. One ... a difference in overall survival between two treatment groups. ...
... West Orange, NJ. December 28, 2011. The 2011 revision ... Spinal Cord Injury (ISNCSCI) was published in the November ... Medicine . The accompanying reference article by Steven Kirshblum ... Both are available for free download via http://www.ingentaconnect.com/content/maney/scm ...
... 2011) Treating ovarian cancer with the drug bevacizumab ("Avastin") ... results of an international clinical trial co-led by Drs. Amit ... and Timothy Perren, St James,s Institute of Oncology, Leeds, UK. ... England Journal of Medicine, report that the drug halted ...
Cached Medicine News:Health News:Even Today, the Stigma of Mental Illness Won't Fade 2Health News:Even Today, the Stigma of Mental Illness Won't Fade 3Health News:'Silent Strokes' Linked to Memory Loss in Elderly: Study 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 3Health News:Avastin May Help Some With Ovarian Cancer: Studies 4Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Ovarian cancer study proves drug delays disease progression, may improve survival 2
... have a direct thermal print surface ... HF-I transponder. When processed through a ... other graphics may be printed at ... programmed to the RFID transponder. Please ...
... The Radianse single-use active-RFID ... and convenience of medical consumables ... of Radianse reusable active-RFID tags. ... patient's ID wrist band, fit ...
... Techno THERM RFID labels are carefully ... materials and RFID antennas. SATO Techno ... and manufactured to ensure optimum performance ... SATO printer / encoders are available ...
PDC Smart® Wrist Tag provides read/write and data storage capabilities....
Medicine Products: